- Home
- LYRA vs TNMG Comparison
LYRA vs TNMG Comparison
Compare LYRA & TNMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- TNMG
- Stock Information
- Founded
- LYRA 2005
- TNMG 2023
- Country
- LYRA United States
- TNMG Japan
- Employees
- LYRA N/A
- TNMG N/A
- Industry
- LYRA Medical/Dental Instruments
- TNMG
- Sector
- LYRA Health Care
- TNMG
- Exchange
- LYRA Nasdaq
- TNMG NYSE
- Market Cap
- LYRA 15.0M
- TNMG 14.1M
- IPO Year
- LYRA 2020
- TNMG N/A
- Fundamental
- Price
- LYRA $7.95
- TNMG $0.45
- Analyst Decision
- LYRA Buy
- TNMG
- Analyst Count
- LYRA 2
- TNMG 0
- Target Price
- LYRA $16.00
- TNMG N/A
- AVG Volume (30 Days)
- LYRA 91.5K
- TNMG 124.5K
- Earning Date
- LYRA 08-13-2025
- TNMG 08-05-2025
- Dividend Yield
- LYRA N/A
- TNMG N/A
- EPS Growth
- LYRA N/A
- TNMG N/A
- EPS
- LYRA N/A
- TNMG N/A
- Revenue
- LYRA $1,185,000.00
- TNMG $48,493,897.00
- Revenue This Year
- LYRA N/A
- TNMG N/A
- Revenue Next Year
- LYRA $139.18
- TNMG N/A
- P/E Ratio
- LYRA N/A
- TNMG N/A
- Revenue Growth
- LYRA N/A
- TNMG 35.31
- 52 Week Low
- LYRA $3.81
- TNMG $0.26
- 52 Week High
- LYRA $37.50
- TNMG $34.08
- Technical
- Relative Strength Index (RSI)
- LYRA 41.08
- TNMG N/A
- Support Level
- LYRA $7.77
- TNMG N/A
- Resistance Level
- LYRA $8.67
- TNMG N/A
- Average True Range (ATR)
- LYRA 0.45
- TNMG 0.00
- MACD
- LYRA -0.03
- TNMG 0.00
- Stochastic Oscillator
- LYRA 11.32
- TNMG 0.00
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About TNMG TNL MEDIAGENE
TNL Mediagene is principally engaged in digital advertising, integrated marketing, marketing survey, artificial intelligence technology, data analysis, content service platform and production of audio-visual programs. Geographically, the company generates the majority of its revenue from Taiwan.